XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Principal Activities - Additional Information (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2023
USD ($)
Segment
shares
Dec. 31, 2022
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Date of incorporation   Apr. 21, 2003  
Headquartered in   South San Francisco  
Headquartered in state   CA  
Number of operating segments | Segment   1  
Accumulated deficit $ 590,473 $ 590,473 $ 452,615
Unrestricted cash, cash equivalents and marketable securities 321,100 $ 321,100  
Substantial doubt about going concern, within one year   false  
Vaxcyte      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Unrestricted cash, cash equivalents and equity securities at carrying value $ 34,000 $ 34,000  
At-the-Market (“ATM") | Common Stock      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Shares of common stock | shares 0 1,857,410  
Gross proceeds from issuance of common stock $ 0 $ 12,400  
Underwriting discounts and commissions and other offering expenses 0 400  
Net proceeds from issuance of common stock $ 0 $ 12,000  
Minimum      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Period from issuance date of unaudited interim condensed financial statements   12 months